Cite
HARVARD Citation
Wynne, C. et al. (n.d.). Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects. Expert opinion on investigational drugs. pp. 1361-1370. [Online].